Skip to main content
Gufic BioSciences Ltd. logo

Gufic BioSciences Ltd. — Investor Relations & Filings

Ticker · GUFICBIO ISIN · INE742B01025 LEI · 3358003C6YDH6EIDBP63 BSE.NS Manufacturing
Open in API
Filings indexed 1,214 across all filing types
Latest filing 2026-06-18 Regulatory Filings
Country IN India
Listing BSE.NS GUFICBIO

About Gufic BioSciences Ltd.

https://gufic.com/

Gufic BioSciences Ltd. focuses on the research, development, and large-scale manufacturing of pharmaceutical formulations and active pharmaceutical ingredients. The organization is distinguished by its specialized expertise in lyophilization technology, operating extensive facilities for the production of freeze-dried injectables. Its product portfolio encompasses a wide range of therapeutic areas, including critical care, infertility, oncology, and gastroenterology. In addition to conventional medicine, the company develops proprietary herbal and ayurvedic formulations through integrated scientific research. Gufic emphasizes advanced drug delivery systems and maintains a significant presence in the production of antibiotics, antifungal agents, and cardiac medications. The company serves a global clientele by providing high-quality generic and specialty healthcare solutions.

Recent filings

Filing Released Lang Actions
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document contains a letter from Gufic Biosciences Limited addressed to stock exchanges about the publication of a newspaper advertisement informing shareholders about a special window for re-lodgement and dematerialization of shares. This is clearly a regulatory announcement about corporate action regarding share transfers and not a financial report. It refers specifically to Regulation 30 of SEBI LODR and includes no financial data or detailed analysis. The document length is about 7,350 characters, and it mainly notifies about a newspaper advertisement, consistent with a notification or regulatory announcement type. It is not an Annual Report, Audit Report, or Interim Report. Nor is it about management changes, dividends, or capital changes. The nature fits best under Regulatory Filings (RNS), which serves as a fallback for regulatory announcements and compliance documentation that does not fall into other categories.
2026-06-18 English
Newspaper Advertisement regarding Special Window for Re-lodgement of Transfer and Dematerialization of physical shares is attached herewith.
Regulatory Filings Classification · 95% confidence The document consists of a letter from Gufic Biosciences Limited addressed to stock exchanges regarding a newspaper advertisement about the commencement of a Special Window for Re-lodgement of transfer deeds and dematerialization of physical shares. This references compliance with SEBI regulations and a specific SEBI circular dated January 30, 2026. The letter requests that this be taken on record and encloses copies of the newspaper advertisement. There is no actual financial data, earnings results, or detailed report content. The length is sufficient but the content is primarily an official notification or announcement regarding regulatory compliance and shareholder information. This fits best with Regulatory Filings (RNS) definition as a general regulatory announcement that doesn't fit other specific categories such as Dividend, Capital changes, or financial results. There is also no indication that it is a publication announcement of a report (RPA) or a management or audit report. The rest of the text appears unrelated, or possibly garbled content, not forming a coherent financial report. Therefore, based on the SEBI regulation mention, the nature of the letter, and the absence of detailed financial data, the classification is Regulatory Filings (RNS).
2026-06-18 English
Written Transcript of Earnings Conference Call held on June 01, 2026 at 04:30 PM is attached herewith.
Call Transcript Classification · 95% confidence The document is the full written transcript of Gufic Biosciences Limited’s Q4 and FY26 earnings conference call, including management remarks, moderator introduction, financial updates, and Q&A. This matches the definition of a Call Transcript (CT).
2026-06-05 English
Corrigendum and Clarification to Intimation dated May 29, 2026 regarding Subscription to Shares of Saraswat Co-operative Bank Limited, is attached herewith
Regulatory Filings Classification · 70% confidence The document is an official regulatory disclosure to BSE and NSE under SEBI (Listing Obligations and Disclosure Requirements) Regulations, providing a corrigendum and clarification to an earlier intimation about the company’s subscription to shares of Saraswat Co-operative Bank. It is neither a financial report (10-K/IR) nor an earnings release, not a board change, not a dividend notice, nor a description of own share transactions (repurchase). It is a general regulatory announcement required by the stock exchange and falls into the fallback ‘Regulatory Filings (RNS)’ category.
2026-06-02 English
General Updates
Regulatory Filings Classification · 80% confidence The document is a regulatory disclosure under SEBI Listing Obligations (Regulation 30) clarifying a previous intimation regarding the company’s subscription of shares in Saraswat Co-operative Bank. It is an update/clarification announcement, not an actual financial report, not announcing a dividend or annual/interim report, nor detailing major management changes. It does not contain substantive financial statements but is a compliance filing. Therefore, it falls under the general “Regulatory Filings” category as a miscellaneous regulatory announcement.
2026-06-02 English
Corrigendum and Collaboration to Intimation dated May 29, 2026 regarding Subscription to Shares of Saraswat Co-operative Bank Limited is attached herewith
Regulatory Filings Classification · 78% confidence The document is an official corrigendum and clarification letter to BSE/NSE under Regulation 30 of SEBI LODR, supplementing a previous intimation about subscribing to shares of Saraswat Co-operative Bank. It contains no financial statements, no management or board changes, no earnings data, and is not a report itself but a regulatory disclosure/amendment. Therefore, it falls under the general regulatory announcements category.
2026-06-02 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.